Part IThe Story
In the middle of the 1960s, on a stud farm on the edge of Pune, horses that had finished racing were led away. They were not sold to other owners or turned out to pasture. They went down the ghats to Bombay, to a government laboratory called the Haffkine Institute, where they would spend the rest of their lives being bled. A horse is a large animal, and a large animal holds a great deal of blood. Inject it with a measured dose of tetanus toxin or snake venom, wait while its immune system does the work, draw off the blood, and the pale fluid that separates from the red cells, the serum, contains antibodies that can save a human life. The Poonawalla family had been giving their retired thoroughbreds to the Institute for years. It was a kind of charity, or a kind of disposal. The accounts were never clear on which.
The young man watching was in his early twenties. He had grown up among bloodlines, the pedigrees and dams and sires, the three-generation charts that a breeder reads the way a banker reads a balance sheet. He was not trained in science and never would be in any formal sense. He had failed to make a sports car profitable, had been forbidden by his father from becoming a bookmaker, and had concluded, by his own account, that the business he was born to inherit was dying. What he saw in those departing horses was not a sentimental loss. He saw an arbitrage. The government was taking the family's most valuable byproduct and turning it into medicine that India was otherwise importing at prices most of the country could not pay.
"Horse serum," Cyrus Poonawalla said nearly six decades later, sitting on a cushioned sofa in the lobby of the Melbourne Convention Centre during a break at the Asian Racing Conference, in the eighty-second year of his life. "I went into the business of making serums and then vaccines." He began to explain the process to a racing journalist: the vaccine given to the horse, the blood drawn, the serum sterilised and processed. Then he stopped himself. "It's a long story, and then you make the product."
The long story is this. Out of that small act of noticing grew the Serum Institute of India, the largest vaccine manufacturer on earth by volume. By the company's own estimate, it supplies at least one dose to roughly half the children born on the planet. It made the Covishield vaccine that went into close to nine of every ten arms in India during the worst of the pandemic. It made its founder one of the richest men in Asia, and it never took a rupee of outside equity. Everything that followed, the private jets and the Rembrandts, the Derby winners and the Oxford doctorate, the fights with prime ministers' governments and the son who would become a global celebrity, traces back to a laboratory in a corner of a stud farm and to one man's recognition that the horses were worth more for their blood than for their speed.
By the Numbers
The Serum Institute Empire
₹5 lakhFounding capital of the Serum Institute of India, 1966
1.5B+Vaccine doses produced annually (about 1.9 billion as of 2023)
170+Countries that use Serum Institute vaccines
₹25,646 crFY22 revenue (about US$3.47 billion), with ₹11,116 cr net income
~100%Share of the Serum Institute owned by Poonawalla, per Forbes in 2007
30M+Lives saved, by Poonawalla's own estimate
287Classic race winners bred by Poonawalla Stud Farms as of 2007
A Fortune Divided by Fourteen
The surname is an address. Poonawalla means, more or less, "the man from Poona." It is a toponym shared across the city's Parsi, Dawoodi Bohra, and Khoja communities, a name that tells you where someone comes from and nothing else. The family that would make it globally recognisable had not been born with it. Cyrus's great-great-grandfather was Dhanjishaw Ankleshwaria, whose own name pointed to Ankleshwar in Gujarat, the region from which the Parsis had spread across western India. Dhanjishaw became a leading contractor in Pune and a figure of enough local weight that people called him "Poonawalla Seth," the merchant-lord of Pune. The honorific outlived the man and hardened into a surname.
Dhanjishaw had eleven sons and three daughters. However large the contractor's fortune had been, fourteen heirs divided it, and their children divided it again, and so on down through the generations. By the time Cyrus was born on 11 May 1941 to Soli and Gool Poonawalla, the family was comfortable and well connected, but it was no longer the dynasty its founder's title implied. Cyrus watched the dilution happen and drew a conclusion simple enough to fit in a joke. He kept his own family deliberately small, and he reportedly said he could not afford more sons. He had one, Adar, born on 14 January 1981. The fortune that son would inherit has not been divided.
This is the first thing to understand about Cyrus Poonawalla, and it is easy to miss beneath the cigars and limousines. He is a breeder. He thinks in lines of descent: what is passed down intact, what is lost in the splitting, how a single strong sire can remake a bloodstock over a few generations. The Parsis of western India are a small, famously endogamous community, descendants of Zoroastrian refugees who reached the Gujarat coast more than a millennium ago, and they have long thought this way too. Their merchant princes, the Tatas and Wadias, the Jehangirs and Jeejeebhoys, built outsized institutions from a tiny population base. (Anyone wanting the texture of that world, its eccentricities and its astonishing record of achievement, could do worse than The Tatas, Freddie Mercury & Other Bawas.) As a teenager, Cyrus was openly drawn to the lives of those great industrial families. He admired how they lived, and he wanted in.
His father offered a narrower inheritance. Soli Poonawalla, an avid racegoer and owner, established a stud farm outside Pune in the 1940s. Cyrus has placed it in the early part of the decade, and the family's official histories fix it at 1946. It was about seventy acres, and the timing was terrible. The Second World War made importing foundation stock from Britain nearly impossible. Then, in 1951, the government banned horse racing for a stretch, which, as Cyrus later put it, "put the clock back" for a breeding industry that had barely started.
The boy loved the place anyway. During school holidays, from the age of four or five, his father took him along every day. He started riding at eight and was soon good enough to go bareback over rough ground. His favourite pony was called Saddleback, "a tough, locally bred pony from a hill station called Mahabaleshwar." He wanted badly to ride in the Amateur Riders' races. Soli forbade it. At fourteen, in protest, Cyrus gave up riding altogether.
That small rebellion, a boy refusing the whole of something because he has been denied the part he wanted, would recur throughout his life. In his teens he bet on races "based on red-hot tips" and worked out that the real money was on the other side of the book. "I realized that becoming a bookmaker would be very lucrative," he told Forbes in 2011, "but Dad put his foot down, saying it was an inappropriate career." By eighteen he was helping run the farm and had been admitted to the Royal Western India Turf Club, the colonial-era institution that governed racing in Bombay and Pune. By twenty, by his own accounting, he had seen the end of it.
— Cyrus Poonawalla, Forbes, 2011I got into vaccines because I soon realized that the king of sport had no future in a socialist country that India was back then.
Consider what "socialist" meant to a twenty-year-old heir to a stud farm in 1961. Jawaharlal Nehru's India was building steel mills and dams under five-year plans. It rationed foreign exchange like water in a drought and licensed private industry through a permit system that later generations would call, with real bitterness, the Licence Raj. In that state, a sport of maharajas and bookmakers had no natural place. Racing depended on imported bloodstock, which required foreign currency the government preferred to spend on turbines. It depended on gambling, which moralists and ministers periodically moved to ban. It depended on a leisured class that the ruling ideology found faintly embarrassing. Forbes, in its 2007 profile, described the young Cyrus as carrying "a bit of bourgeois guilt and an independent streak." Either would have been enough to push him toward the door. He had both.
His first attempt to leave was about as unsocialist as possible. With a school friend named Don Patrick, he built a sports car prototype modelled on the Jaguar D-type, the curvaceous machine that had won Le Mans three years running in the mid-1950s. They named it the Cydon, fusing their first names the way one might name a foal after its sire and dam. The prototype reportedly cost $120 to build. Building it commercially would have cost vastly more than two young men in Pune had, and in a country where the Hindustan Ambassador was a waiting-list luxury, a home-grown sports car was a fantasy. The Cydon was abandoned. The passion for cars was not. It would reappear decades later in a temperature-controlled garage full of sports cars and custom-built limousines.
The more important lesson from the Cydon, which Cyrus seems to have absorbed quickly, was about markets rather than machines. A sports car is a product for the few. Racing is a sport for the few. His family's fortune had been built by serving the elite, and in 1960s India the elite was a shrinking, politically suspect market. A later summary of his thinking, published on the group's own website, put it bluntly: he "realized that creating a product for the masses than for the elite would be a smarter move." It reads like corporate hindsight, the sort of line written after the outcome is known. But the facts support it. His next venture served nobody but the masses.
Accounts differ on exactly how he found vaccines. One version, repeated in several profiles, has a chance meeting with a veterinary doctor, who explained what the Haffkine Institute was doing with the farm's retired horses. Another version, recently circulated in the motivational corners of LinkedIn, involves a horse killed by a snakebite because antivenom arrived too late. I have found no primary source for that one, and it has the too-neat shape of a legend assembled after the fact. The version Cyrus himself tells is flatter and more convincing. There was not enough money in breeding horses. The horses already went to a government lab for their blood. The government was not very good at making the product. He could do it better and cheaper.
In 1966, the same year he graduated with a commerce degree from Brihan Maharashtra College of Commerce, where a classmate named Sharad Pawar was starting a political career that would run for half a century, Cyrus Poonawalla founded the Serum Institute of India. "I started my journey as an entrepreneur in 1966 with a capital of ₹5 lakhs," he said in 2026, "to set up a small-scale manufacturing plant to manufacture sera and vaccines." Five lakh rupees was a real sum then, but it was not a fortune. It was the sort of money a well-off Parsi family could put into a son's venture without betting the farm. And the venture sat, quite literally, on the farm: a small laboratory set up in a corner of the stud.
He knew nothing about immunology. So he hired people who did. He brought in doctors and scientists from the Haffkine Institute itself, the same government lab that had been taking his family's horses. It was a neat reversal. The institution that had processed the Poonawalla bloodstock now supplied the Poonawalla payroll. The first product, a tetanus antitoxin, came out in 1967. Anti-snake-venom serums, which Forbes described as then "in short supply in the country," followed. Both were drawn from the blood of horses. For its first years, the Serum Institute was a stud farm with a second crop.
The Price of a Cup of Tea
The Serum Institute's product timeline reads like a slow inventory of the diseases that killed Indian children. In 1974 it introduced a DTP vaccine against diphtheria, tetanus, and pertussis, or whooping cough. In 1981 came a refined anti-snake-venom serum for a country where snakebite killed tens of thousands a year. In 1989 came M-Vac, a measles vaccine. Within a year of M-Vac's launch, the company became the largest vaccine manufacturer in India, a position it has never given up. By the end of the 1980s, the country that had imported its immunobiologicals at high prices was, thanks largely to one private company in Pune, self-sufficient in vaccines for tetanus, diphtheria, and whooping cough.
The company did not win because its science was better. It won on cost and on the government's clumsiness. In the early 1970s, as the global campaigns against smallpox and polio gathered pace, Indian vaccine production depended mostly on state laboratories. A later account described them as burdened by "rigid bureaucracy, high manufacturing cost, and sleepy service delivery." A private firm with one owner, no shareholders, and no ministry to answer to could move faster and produce more cheaply. Poonawalla used that agility to win contracts from national and state governments. The irony would have pleased him. The socialist state that had made racing unviable became the biggest customer of the business he built to escape racing. Five-year plans needed vaccines, and the Serum Institute sold them at a price no one else could match.
Around this time Poonawalla adopted a slogan borrowed from the public-health vocabulary of the era: "Health for all by 2000 AD." Coming from a man who would later collect Rubens paintings, it sounds almost comically earnest. But the slogan contained a business model. Getting every child vaccinated means selling to every government, and every government pays in tenders, and a tender is won by the lowest credible bid. A manufacturer committed to universal coverage is, by definition, committed to being the cheapest producer. Poonawalla's idealism and his cost structure were the same thing described in two vocabularies. Which came first, the conviction or the arithmetic, is the question people have kept asking about him for sixty years, and he has never seemed especially interested in answering it.
Then came 1994. That year the World Health Organization accredited the Serum Institute to supply vaccines to United Nations agencies, which opened the company to UNICEF and the Pan American Health Organization. "In 1994 we got World Health Organisation recognition and that opened up a whole new opportunity for us," Adar Poonawalla told The Times in 2011. The effect was nearly immediate. A specialist manufacturer serving the Indian market became a global supplier almost overnight, undercutting GSK, Pfizer, and the rest of the multinational establishment in exactly the markets those companies had never much wanted: the poorest countries, buying through UN procurement, at prices measured in cents. By 1998, the company was exporting across the world. By around 2000, its vaccines were reaching one of every two children on earth. UNICEF became its biggest customer.
The prices became legend. One industry account from 2019 noted that many of Serum's vaccines against measles, rubella, diphtheria, pertussis, tetanus, and hepatitis B were available to UN agencies "at prices that are less than that of a cup of tea." The Times headlined its 2011 profile with a quote that sounded less like a mission statement than a threat: "We crashed global prices." By then the company was making around 80 percent of all the measles vaccine in the world. The measles doses it supplied to UNICEF and PAHO between 1990 and 2016 are estimated to have prevented some 22 million deaths.
The part that makes this a business story and not a charity story is what the same Times piece recorded almost in passing. Serum was "a hugely profitable enterprise," with sales of up to $300 million a year, "about half of which is pure profit." Forbes had reported similar figures four years earlier: net profits of $107 million on sales of $250 million. A company selling vaccines for less than the price of tea was clearing margins a luxury-goods house would envy. There was no trick. The volumes were so enormous, and the costs driven so relentlessly down, that a fraction of a cent above cost multiplied by hundreds of millions of doses became a fortune. The cheapness was the moat, and it was very deep.
Answerable to No One
In November 2007, the investment bankers came courting. Forbes Asia's Naazneen Karmali counted seven of them, all trying to take the Serum Institute public, with valuations ranging from $4 billion to $10 billion. Poonawalla owned almost all of it. An IPO would have made him one of the most celebrated tycoons in the new, liberalised India that was then throwing off listed billionaires at a startling rate. He received the reporter in the rarest of settings, an actual interview, and puffed on his cigar.
"We don't really need the money," he said. "And I don't fancy the idea of being answerable to anyone."
It is one of the clearest statements of corporate philosophy any Indian industrialist has made, and it has two halves that are worth pulling apart. The first is simple financial fact. A business clearing 40 to 50 percent net margins, growing on its own cash flow, with a monopolistic grip on a market no multinational wanted, did not need outside capital. The second half is temperament. Poonawalla was the boy who quit riding because his father would not let him race. He was the teenager who wanted to take the other side of the bets. The man was not going to take questions from fund managers in Boston about the gross margin on a pentavalent vaccine.
Four years later, in the "baronial boardroom" overlooking his manicured stud farm, he told The Times the offers had not stopped. "We get offers every month from Big Pharma, private equity – but we don't want to sell," he said, glancing at his thirty-year-old son. "Why would we?"
— Cyrus Poonawalla to The Times, November 2011We get offers every month from Big Pharma, private equity – but we don't want to sell. Why would we?
The best answer to that rhetorical question came in 2026, from an unexpected direction. At a Hurun India event in the Deccan, the researcher Anas Rahman Junaid asked Poonawalla why he had charged so much less for his vaccines than he could have. Junaid then posted his own back-of-envelope estimate. Had Serum priced at competitor levels, he reckoned, Poonawalla's wealth would be somewhere around $60 to $70 billion, and more once compounding was counted. In the conversation, Poonawalla described consciously choosing a less commercial approach, and he tied that choice directly to keeping the company private. Being private was what made the underpricing possible. A listed company that left tens of billions of dollars on the table over decades would have faced activist investors, class actions, and a board demanding "price discipline." A private company answering to one man could decide that a dose of measles vaccine for a child in Chad would cost what it cost.
This is the hinge of the Poonawalla story, and it swings both ways. The same unchecked authority that let him keep prices low also let him keep a garage full of limousines, a disco in his basement, and later a pair of long-range business jets, without anyone asking whether the capital might be better deployed. Privacy protected the mission and the indulgences alike. It is difficult, and probably pointless, to separate them.
Privacy did not make him infallible. At some point the family and affiliated entities built up a stake of around 14 percent in Orchid Pharma, a listed Chennai drugmaker, apparently hoping to acquire it. It went badly. Cyrus filed a petition alleging oppression and mismanagement. "Investments in Orchid Pharmaceuticals was perhaps the single mistake we have ever made," Adar said in October 2018, describing debt that Orchid's management "kept taking … without anyone's consent." The one serious misstep came when the Poonawallas became minority shareholders, answerable to someone else's decisions and unable to control them. The lesson was the 2007 quote with the roles reversed.
In June 2005, India Today ran a supplement profile under a headline calling the Poonawallas "India's most reclusive billionaires." The photograph showed Cyrus stepping off a private Citation Excel jet, which he had added to his collection the year before. The reporter, Kimi Dangor, listed the inventory: thoroughbred racehorses, vintage cars in a temperature-controlled garage, Rubens and Rembrandts on the upper walls of the Pune mansion, a discotheque in the basement. Then she recorded the line that makes the whole profile hum. The patriarch, she wrote, calls himself "a socialist at heart."
It is tempting to take this as pure hypocrisy, the kind of thing rich men say to feel better about their ceiling frescoes. There were frescoes. Forbes reported in 2007 that the domed living-room ceiling of the 40,000-square-foot English-style manor was covered with replicas of Michelangelo's Sistine Chapel frescoes, "all handpicked by his wife, Villoo." Picture God reaching toward Adam above the sofas of a Parsi billionaire in Pune, with a nightclub two floors below. A reader can be forgiven a smile.
But the phrase deserves more than a smile, because "socialist" is the word Cyrus Poonawalla has used, at intervals of decades, to describe three quite different things. In 1961, socialism was the force that made his family's business obsolete: racing had "no future in the socialist India of the time." In 2005, it was his own heart: a claim, however stagey, that the vaccines for a cup of tea expressed a real conviction. In 2023, as we will see, it was the name he gave to a government decision that kept him out of his own house. The word works as an enemy, an identity, and an insult, depending on the year. Few people have used one political term in so many ways. That he does not appear to notice the contradictions is part of what makes him interesting.
Villoo was central to all of it, the aesthetic and the social life and the racing. She chose the frescoes. She was a real presence on the turf, and when she died of cardiac arrest on 8 June 2010, at sixty-seven, the racing press ran tributes under headlines about the void she left. Within a year Cyrus had started the Villoo Poonawalla Foundation, working in education, healthcare, and water and sanitation, and it eventually built a multispecialty hospital in Pune in her name. In 2019 he republished a small Zoroastrian prayer book, Mazda-Yasna, in Roman script with English translation, for free distribution to Parsi youth who could not read the Gujarati text of the traditional Khordeh Avesta. It was dedicated to her memory. His note on the project included a line that could serve as a whole theory of religious practice, and possibly of manufacturing: "Pray less – Pray correct!"
The horses, meanwhile, finally prospered, because the vaccines paid for them. "In those days we couldn't afford the best stock or breeds," he wrote of the farm's early decades. "It took off much later, when I started pumping in money from the vaccines business. We started acquiring land and buying good bloodstock." The seventy acres grew to five hundred. An imported stallion named Satinello sired Potential Champion, a filly who won the Indian 1000 Guineas and the Indian Oaks in 1980, which made the farm, in Cyrus's careful phrase, "marginally profitable." Two more stallions followed, Malvado and Riyahi, the latter from the Aga Khan's famous stable. Riyahi sired Cordon Bleu, the farm's first Indian Derby winner, in 1988. The following year a colt called Exhilaration won the Derby in Cyrus's own colours and retired unbeaten after nine races. "My favorite," he said. Then came Astonish, winner of the Indian Triple Crown, who went on to take a HK$1 million purse in Hong Kong in 1993–94. In 2007 Mystical became the first Indian horse to win two races at the Dubai International Racing Carnival. By that year the farm had bred 287 classic winners.
Stated plainly, the causality is remarkable. The horses gave their blood to the vaccines, and the vaccines, decades later, gave the horses their pedigree. The farm that Cyrus had declared doomed at twenty was saved by the business he founded to escape it.
He never escaped racing's politics, and he never really tried. In 1974 he was elected to the committee of the Turf Club and later became a steward, arriving, as he put it, with "a burning desire to clean up the sport, which had always carried the stigma of gambling and manipulation." This from the teenager who had wanted to be a bookmaker. He rose to honorary chairman of the Royal Western India Turf Club. In 2006 Vijay Mallya, the flamboyant liquor baron who would later flee India owing banks billions, tried to unseat him and failed. The one kind of competition Cyrus Poonawalla has consistently lost gracefully is the horse race itself. "The sport of horse racing and breeding is one of great agony and ecstasy," he wrote. Nobody has ever caught him describing the vaccine business that way.
The Prince in the Pandemic
Adar Poonawalla joined the Serum Institute's sales team in 2001, fresh from the University of Westminster. The company was then exporting to about 35 countries. The son travelled, sold, pushed, and, by one account, took the number of export markets to around 140. He rose steadily. In 2011, the year after his mother died, he became CEO at thirty. In the Times interview from that November, the camera catches the father glancing "fondly" at the son while swatting away private equity.
In one sense the handover was complete, and in another it never happened. Cyrus remains chairman and managing director. He kept the voice. Adar ran the operations, and the international expansion that followed was mostly his: the 2012 acquisition of Bilthoven Biologicals in the Netherlands, the group's first international purchase; the partnership with Oxford's Jenner Institute that would later produce the R21/Matrix-M malaria vaccine, recommended by WHO advisers in October 2023, with capacity for 100 million doses a year; the 2021 purchase of a 61.5 percent stake in Magma Fincorp for ₹3,210 crore, renamed Poonawalla Fincorp. The father watched, commented, and sometimes contradicted.
Then the pandemic arrived and made Adar one of the most famous businessmen in the world, and one of the most exposed.
In 2020, while the Oxford-AstraZeneca vaccine was still in clinical trials and nobody knew whether it would work, Adar committed the company to making it at a scale no manufacturer had tried. He spent some $800 million on chemicals, glass vials, raw materials, and capacity, and he needed to raise nearly $1 billion to make the plan work. "It was a calculated risk," he told CNN. "But I didn't see the choice at that time, to be honest. I just felt I'd regret not committing one way or another." The vaccine, branded Covishield, was priced at around ₹225, roughly $3 a dose, for low- and middle-income countries through COVAX. It won emergency approval in India in January 2021. The Gates Foundation and WHO-linked partners advanced money against future supply to the poorest nations.
Then, in April 2021, India's second wave hit and the government banned vaccine exports. The company that had promised doses to the world could not deliver them, and 150 countries, as Cyrus later put it, were "blaming the company for stopping the supply during a crucial period." At home it was worse. Adar left for London and stayed there. He told The Times that powerful people had threatened him while demanding doses. "Everything falls on my shoulders, but I can not do it alone," he said. He returned only after the government gave him armed security.
The father spoke in August 2021. He was eighty, receiving the Lokmanya Tilak National Award in Pune, and he dedicated it to Villoo. Then he said what his son had evidently begged him not to say.
"My son asked me not to open my mouth," Cyrus Poonawalla said. "But it is my view that exports ought to be opened."
He called the export ban "a bad move by the government." He revealed that the Gates Foundation and WHO had given the company ₹5,000 crore in advances, and that he had offered to return it; they declined, he said, apparently hoping the ban would soon lift. He poured cold water on the national target of vaccinating every Indian by the end of 2021: "No single company in the world can produce 10 crore vaccines in a month. We have promised about 110-120 crore doses annually because we invested in it prior. So you can do the math now." In the same appearance he attacked a proposed trial of mixing Covishield with the rival Covaxin. His objection was not immunological so much as legal: if the mix misfired, "Serum will say that the other vaccine is not good and they will blame us." Then he added, "I think it is very wrong to mix the vaccines and you can quote me."
It was the old temperament with nothing filtering it. In the same breath he praised the Modi government for cutting red tape: "I am not the one to give lip sympathy to government ministers but certainly, one of the major reasons why we could launch our Covid vaccine so quickly was because of the forthcoming grant of permissions, encouragement to industries and reduction of 'Licencing Raj'. We have now got a drug controller who responds in the evening hours." The man who had started his company under the Licence Raj was now thanking a regulator for answering the phone after six. He meant it as the highest compliment available.
The pandemic finished what 1994 had started. The Serum Institute's FY22 revenue reached ₹25,646 crore, about $3.47 billion, with net income of ₹11,116 crore. Forbes India's 2022 list ranked Cyrus the fourth-richest person in the country, citing "bumper profits from COVID-19 vaccines." The Government of India awarded him the Padma Bhushan that year specifically for vaccine production during the pandemic. Years later, asked by the Financial Express what he most wanted to be remembered for, he did not name the fortune.
— Cyrus Poonawalla to FinancialExpress.com, 2026There was always pressure to price higher, to maximise margins, and I understand the business logic of that. But it was never what drove us. During COVID-19, especially when the whole world was watching and the demand was unlike anything we had ever seen, we held the line.
The Doctor Who Never Studied Medicine
He is "Dr. Cyrus Poonawalla" in every press release, every plaque, every group communication. The title is earned, though not in the usual way. In 1988, twenty-two years after founding the company, Pune University awarded him a PhD for a thesis titled "Improved Technology in the manufacture of specific Anti-toxins and its socio-economic impact on the Society." The subject was his own company, anti-toxins drawn from horse blood, and the second half of the title reveals what he cared about: not just the technology but its socio-economic impact on society. The businessman who had hired the Haffkine scientists because he knew no immunology went back and wrote the dissertation on what they had built.
After that the honours piled up. The Padma Shri in 2005. Ernst & Young's Entrepreneur of the Year for India in 2015. On 3 June 2018, in Worcester, Massachusetts, the University of Massachusetts Medical School made him a Doctor of Humane Letters at its forty-fifth commencement. His own website noted, pointedly, that past recipients included Barack Obama and Anthony Fauci. On 26 June 2019, at Oxford's Encaenia ceremony, he received a Doctor of Science honoris causa. His website adds that he was "the only person who has been honoured with this degree after Dr. Edward Jenner, who was honoured in the year 1813 in the field of vaccines." That is his claim, not Oxford's, and it is a characteristic one: the horse breeder's son placing himself in the direct line of descent from the man who invented vaccination. In November 2019 Bill Gates presented him with the ICMR Lifetime Achievement Medal. In May 2022 came the Dean's Medal from Johns Hopkins Bloomberg School of Public Health.
What to make of all this? Partly it is the accumulated honour of a long and consequential career. Partly it is something else: a man managing, with some care, how his life will be read. When the Pune felicitation for the Massachusetts degree was held in August 2018 at the J W Marriott, the guests included Sharad Pawar, who recalled their shared college days, and the film stars Sanjay Dutt and Mallika Sherawat. Speaking there, Cyrus attributed his awards to "god's blessings." Pawar mentioned that Poonawalla had been nominated for the Nobel Prize. The number Poonawalla returns to most often, "more than 30 million human lives" saved, is his own estimate. It is plausible, even conservative given the measles figures alone, but it is his.
He also knows how to be blunt about failure when the failure belongs to someone else. At a March 2015 convocation in Mumbai he lamented that India's immunisation rates were lower than those of Bangladesh, Nepal, and some sub-Saharan countries. For the man whose company supplied half the world's children, this was a strange confession about his own country. In September 2019 he told CNBC-TV18 that Serum had to run its dengue vaccine trials in Australia "because in India they have been very slow in giving us the necessary clearances." He added, "The government must walk the talk." He complained that government tenders were squeezing manufacturers and that Indian vaccine prices were the lowest in the world. He did not pause to note that the lowest price in the world was largely his own doing.
And he will say things to old friends that most men would not. In August 2023, with Pawar, then eighty-two, preparing for an opposition alliance meeting in Mumbai, Poonawalla told reporters that his college classmate had twice had the chance to become prime minister and it was now time to retire. Six decades of friendship, and he delivered the advice in public. Outspoken, honest to the core, speaks his mind: that is how Cyrus would describe his son. He could be describing himself.
The House He Cannot Enter
Lincoln House stands on two acres of Breach Candy, one of the most exclusive stretches of south Mumbai's seafront. The Maharajah of Wankaner built it in 1938. In 1957 it was sold to the United States government on a 999-year lease, and for more than half a century it served as the American consulate: the building where generations of Indians queued for visas to the country they hoped would make them rich. In 2014 the consulate moved to a larger plot in the Bandra-Kurla Complex and put the old palace up for sale. In 2015 the Poonawalla family bought it for around $120 million, then the most expensive residential deal in the city's history. The plan, according to a 2015 interview, was to use it on weekends.
By 2023 they still had not moved in. Maharashtra state and India's defence ministry both claimed the land, and the central government had frozen the transfer. The US embassy said it was "working with the government of India to reach a satisfactory agreement." A former US secretary of state had raised it. The house decayed.
Poonawalla, eighty-one, spoke about it in Dubai in an interview that Bloomberg's reporters thought unusual, since most Indian tycoons kept their grievances with the government to themselves. "The government of India is not providing any rationale for holding it up," he said. "From what I understand, they don't want this huge amount of about $120 million to go to the US. It's just a political and socialist decision."
There is the word again. The ideology he blamed at twenty for ending his father's industry, and claimed at sixty-four as the truth of his own heart, was at eighty-one the reason a billionaire could not sleep in a maharajah's palace by the sea. In one sense nothing had changed. The Indian state was still deciding, on grounds it did not explain, what a Poonawalla could and could not do. In another sense everything had. The boy had been at the state's mercy. The old man could criticise it from Dubai and expect to be printed.
Money and influence had limits of other kinds as well. In 2024 a plan to put a Poonawalla-funded convention centre, restaurant, and vintage car museum on nine or ten acres of Savitribai Phule Pune University's wooded campus, next to a statue of B.R. Ambedkar, ran into student protests. The students raised the trees, the statue, and the fear that a private enclave would shut them out. A management council member complained that "what began as a Rs 100-crore project escalated to Rs 200 crore." In August 2024 the Cyrus Poonawalla Group withdrew. The same university had given its founder a lifetime achievement award that year. He had attended its affiliated college. The man who once built a car museum into his own home could not build one onto his alma mater's campus.
He buys what he can. In 2026 he paid a record ₹167 crore for Yashoda and Krishna, a painting by Raja Ravi Varma, the nineteenth-century artist who first painted Hindu gods in the European academic manner, and called it a national treasure. The subject is a mother holding her child. Whether he saw a connection to his own life's work, or simply wanted a great painting, is the sort of question he would probably wave away with his cigar.
What Is Passed Down
In April 2022, at an awards evening in Mumbai, CNBC-TV18 sat three generations of Poonawallas in front of a camera, all in suits. There was Cyrus, eighty, recently awarded the Padma Bhushan; Adar, forty-one, CEO; and Adar's elder son, twelve, whose name is also Cyrus.
The interviewer asked the patriarch to describe his son. "Outspoken, honest to the core and speaks his mind," he said. Did he want his grandson to have the same qualities? "I would want Cyrus to have the same qualities," he said, "but in a more refined manner because he is now going to be trained in UK."
It is a very funny line, and like most of his funny lines, it is also exact. A breeder is always trying to keep the strength of a line while improving the finish. The first Poonawalla Seth made money in Pune as a contractor, and his fortune scattered among fourteen children. Soli bred horses on seventy acres in a socialist country that had no use for them. Cyrus bled those horses into a global enterprise and kept it whole by having one son. Adar took it to 140 countries and through a pandemic. The boy, who told the interviewer he liked acting but would follow his father and grandfather, is to be refined in England: outspoken, but with better manners. Adar said he had taught his sons, Cyrus and Darius, to put integrity and public health first, "business and success can come later."
In Melbourne the following year, Cyrus told the racing reporter that he had preferred the two Gulfstreams the family used to fly, "but my son (Adar) didn't like them as much so we changed to the Global 6500." Two Bombardier jets, range 6,500 nautical miles, chosen by the heir over the father's objection. In April 2026, accepting the Economic Times Lifetime Achievement Award, he said: "It is my dream and hope that my son Adar, as CEO of Serum Institute, along with his dedicated staff, will continue my lifetime's work of protecting the underprivileged children of the world in future." Asked what he might have done differently, he allowed that the company could have "moved faster, particularly expanding global partnerships sooner. However, we have generally taken a cautious and sustainable approach." It is the only regret he seems ever to have admitted, and he framed it as a virtue.
In December 2025, a health worker from Himachal Pradesh named Kamla Devi was flown to Pune as a guest of the Serum Institute. That monsoon, amid floods and landslides, she had jumped across a swollen river to reach an infant waiting for a vaccine. There is video of it: a woman in a salwar kameez leaping from rock to rock over brown, roaring water, the vaccine carrier on her shoulder. She had probably never boarded a plane before. In Pune, the eighty-four-year-old chairman honoured her and handed her a reward.
It was ₹5 lakh.
Part IIThe Playbook
What follows distils the Poonawalla method into principles an operator can use. Some are counterintuitive, some uncomfortable, and several contradict the conventional wisdom of modern venture-backed company building. That is the point. Cyrus Poonawalla built one of the most profitable manufacturing enterprises in the developing world by refusing almost every piece of advice a contemporary board would give him: raise capital, list the company, price for margin, professionalise the succession, stay out of politics. Each principle below draws on the evidence from Part I.
The principles
- 1.Look for the asset hiding in your waste stream.
- 2.Flee the shrinking elite market; serve the growing mass one.
- 3.Make cheapness your moat, not your sacrifice.
- 4.Hire the incumbent's talent before you fight the incumbent.
- 5.Pursue the single credential that unlocks a continent.
- 6.Treat ownership as a license for discretion.
- 7.Let the engine fund the passion, never the reverse.
- 8.Build capacity before the crisis asks for it.
- 9.Criticise power specifically, and praise it just as specifically.
- 10.Hand over operations early; keep the voice.
- 11.Go slow where you are a stranger.
- 12.Write your own citation.
Principle 1
Look for the asset hiding in your waste stream
The founding insight of the Serum Institute was not scientific. It was an accounting insight. The Poonawalla stud farm produced two outputs: racehorses, which had declining value in 1960s India, and retired racehorses, which the family was effectively giving away to a government lab. The second output was the valuable one. The Haffkine Institute understood this; the family did not, until Cyrus looked at the departing animals and asked what they were really worth.
Most businesses have a version of this: a byproduct, a dataset, a relationship, or an overlooked capability that someone else is quietly monetising. The discipline is to audit your own outflows with the same seriousness you give your products. Where do things leave your business for free or cheaply? Who receives them, and what do they turn them into? Poonawalla's great-great-grandfather built a fortune; his father built a stud farm; he built an empire from what the stud farm threw away.
Tactic: List every asset, byproduct, or capability that leaves your organisation for free or at a discount, and identify who downstream is capturing its value.
Principle 2
Flee the shrinking elite market; serve the growing mass one
At twenty, Poonawalla concluded that horse racing had "no future in the socialist India of the time." The Cydon sports car taught the same lesson a second time. A product for the few, in a country whose politics distrusted the few, was a trap. So he pivoted to the one customer that would only grow: every child born in India, and eventually every child born anywhere.
The broader lesson concerns reading political and demographic direction as a market signal. Poonawalla did not argue with Nehruvian socialism; he sold to it. The state that made racing unviable became his largest customer. He matched his business to where the political economy was heading, not where his inheritance stood. Founders often build for the market they grew up in. The better question is which market the next thirty years of policy, demography, and ideology will expand, and whether you can be its cheapest supplier.
Tactic: Identify the political or demographic force most hostile to your current market, and ask what product that force would actually buy.
Principle 3
Make cheapness your moat, not your sacrifice
The popular reading of the Serum Institute is that Poonawalla chose impact over profit. The numbers argue otherwise. In 2007 the company earned $107 million on $250 million of sales; in 2011, The Times reported roughly half of sales as pure profit. The vaccines cost less than a cup of tea, and the company was among the most profitable manufacturers in Asia. Cheapness was not charity. It was the moat.
Low prices at enormous volume do three strategic things at once. They lock out competitors who cannot match the cost structure. They make the company indispensable to institutional buyers such as UNICEF, PAHO, and national tenders, whose budgets are fixed and whose mandates are universal. And they create political goodwill that protects the business when governments turn hostile. Hurun's estimate that Poonawalla forwent $60–70 billion by underpricing is probably right in isolation, and probably wrong in practice: at competitor prices, Serum might never have become the world's largest vaccine maker at all.
$
The Economics of the Cheapest Dose
How low price and high margin coexisted at the Serum Institute.
| Conventional pharma logic | The Serum Institute approach | Effect |
|---|---|---|
| Price to what wealthy markets will bear | Price to what UN agencies and poor governments can pay | Scale Volume in the billions |
| Protect margin per unit | Drive cost per unit relentlessly down | Moat Rivals cannot follow |
| Focus on developed markets | Serve 140+ countries outside North America, Australia, EU | Position Uncontested territory |
| List to fund growth | Fund growth from roughly 40–50% net margins | Control Near-total ownership |
| Raise prices in a crisis | "We held the line" on COVID pricing | Risk Political exposure, long-term trust |
Tactic: Model what your business looks like at one-tenth the price and ten times the volume; if the margin survives, that is your moat.
Principle 4
Hire the incumbent's talent before you fight the incumbent
Poonawalla had no medical or biotechnology training. His solution was to hire doctors and scientists from the Haffkine Institute, the same government laboratory that had been processing his family's horses and making the products he planned to undercut. He did not try to out-science the incumbent. He recruited its science and gave it a faster, cheaper, owner-operated home.
This is an underrated form of competitive strategy. Incumbent institutions, especially state or bureaucratic ones, often contain excellent people constrained by slow processes. A founder who offers those people agility and a clear mission can buy the incumbent's capability without buying its dysfunction. Poonawalla's later PhD, awarded in 1988 for a thesis on the technology his own company had developed, suggests he eventually mastered the domain. But he started by renting mastery, and he rented it from his future competitor.
Tactic: Identify the three most capable people at the slowest incumbent in your market, and design a role that offers them speed they cannot get where they are.
Principle 5
Pursue the single credential that unlocks a continent
For twenty-eight years the Serum Institute was a domestic champion. Then, in 1994, WHO accreditation arrived, and "almost overnight," in The Times's phrase, the company became a global supplier. By 1998 it was exporting worldwide; by around 2000, its vaccines reached one in two children on earth. A single regulatory credential did more for the company's scale than any product launch.
In many industries, a small number of gatekeeping certifications, prequalifications, or procurement listings control access to entire buyer classes. They are slow and expensive to get, which is exactly why they are valuable: once earned, they separate you from every competitor still waiting. Poonawalla's operational discipline of quality, consistency, and scale was, among other things, a long campaign to qualify for the one stamp that mattered.
⏱
The Serum Institute's Compounding Decades
Key decisions and inflection points across six decades.
1966
Founded with ₹5 lakh in a corner of the family stud farm; scientists hired from the Haffkine Institute.
1967
First product: tetanus antitoxin drawn from horse serum.
1974
DTP vaccine launched; India moves toward self-sufficiency.
1989
Measles vaccine M-Vac; within a year, India's largest vaccine maker.
1994
WHO accreditation opens UNICEF and PAHO procurement.
2001
Adar joins sales; export markets grow from about 35 toward 140.
2007
Seven bankers pitch an IPO at $4–10 billion. Declined.
2011
Adar becomes CEO; Villoo Poonawalla Foundation established.
2012
First international acquisition: Bilthoven Biologicals, Netherlands.
2021
Covishield approved; export ban; Poonawalla Fincorp acquired.
2023
R21/Matrix-M malaria vaccine recommended by WHO advisers.
Tactic: Name the one certification or listing that would open your largest untouched buyer class, and staff a dedicated effort to earn it.
Principle 6
Treat ownership as a license for discretion
"We don't really need the money. And I don't fancy the idea of being answerable to anyone." Poonawalla's refusal to list the Serum Institute in 2007, and to sell it in 2011, is usually read as stubbornness or vanity. It was also strategic. Near-total ownership let him price below what any outside shareholder would have tolerated, hold COVID prices when the world would have paid more, and choose affordability over margin for sixty years. He tied the pricing choice explicitly to keeping the company private.
The counterexample proves the rule. The one investment his son called "the single mistake we have ever made" was a minority stake in Orchid Pharma, where the Poonawallas had capital at risk and no control over management that "kept taking" debt "without anyone's consent." Discretion needs control. Without it, even a gifted operator is just another shareholder watching someone else make decisions.
Tactic: Before taking outside capital, write down the three decisions you most want to keep making freely, and test whether each investor's return expectations permit them.
Principle 7
Let the engine fund the passion, never the reverse
The Poonawalla stud farm struggled for decades. "In those days we couldn't afford the best stock or breeds," Cyrus recalled. "It took off much later, when I started pumping in money from the vaccines business." The farm grew from seventy acres to five hundred, imported stallions from the Aga Khan's stable, and produced Derby winners and a Triple Crown champion, all paid for by vaccines.
The sequencing matters. Poonawalla did not try to make his passion into his business; he built a business that could afford his passion. Many founders get this backwards, forcing a beloved but structurally weak market to carry a company. He kept racing emotionally central and financially dependent. The cars, the jets, the art, and the horses were all downstream of a cash engine that never needed them.
Tactic: Separate your passion project from your cash engine on paper, and fund the former only from the surplus of the latter.
Principle 8
Build capacity before the crisis asks for it
When India's pandemic targets collided with reality in 2021, Poonawalla explained plainly why his company could deliver at all: "We have promised about 110-120 crore doses annually because we invested in it prior." Adar's $800 million commitment to Covishield raw materials and capacity, made while the vaccine was still in trials, was only possible because the company had decades of spare industrial muscle and the financial independence to bet without asking permission.
Crises reward whoever already has the capacity, not whoever can build it fastest. The Serum Institute's advantage in 2020 was built across fifty years of overbuilding for volume. Its later work on a Nipah virus vaccine reserve with CEPI and a H5N1 pandemic-preparedness platform shows the lesson has been institutionalised. The same crisis also showed the limit: capacity is useless if governments can seize the output, as the April 2021 export ban demonstrated.
Tactic: Identify the crisis your industry is most likely to face in the next decade, and invest now in the capacity you would need on day one of it.
Principle 9
Criticise power specifically, and praise it just as specifically
Poonawalla is, as Bloomberg's reporters noted, a rare Indian tycoon willing to criticise the government in public. He called the 2021 export ban "a bad move." He complained that India's slow approvals forced dengue trials to Australia and told the government to "walk the talk." He called the Lincoln House freeze "a political and socialist decision." In the same breath, he credited the Modi government for cutting the Licence Raj and producing "a drug controller who responds in the evening hours."
This pairing is the craft. Specific criticism attached to specific praise reads as judgement, not opposition. It lets a businessman stay outspoken without being filed as an enemy. Poonawalla's frankness, even against his son's wishes ("My son asked me not to open my mouth"), has seemingly cost him little, because it is precise, tied to concrete harms, and balanced by concrete credit.
Tactic: When you criticise a regulator or partner publicly, name one specific thing they have done right in the same statement.
Principle 10
Hand over operations early; keep the voice
Adar became CEO at thirty, in 2011, a decade after joining sales. It was early by the standards of Indian family business, and it let the son build the international expansion, the acquisitions, and the pandemic bet on his own authority. Cyrus stayed chairman and managing director and kept speaking. He described his son as "outspoken, honest to the core," and occasionally overruled him in public.
The model separates execution from voice. The founder hands over the machinery while it is still growing, so the successor earns legitimacy through results rather than inheritance. The founder remains the conscience and the institutional memory, the one who can say what the CEO cannot. It is not tidy governance, but it has produced a smooth transfer of one of Asia's largest private fortunes, with the third generation already named, schooled, and publicly promised to the business.
Tactic: Set a date to hand your successor full operational authority while the business is still growing, and define in writing the few issues on which you will keep speaking.
Principle 11
Go slow where you are a stranger
In 2019, describing the family's new lending business, Cyrus was explicit: "We have lent out Rs 1,000 crore. We are going slow because we don't want defaults." The Orchid Pharma episode had shown what happens when the family moves into terrain it cannot control. Asked in 2026 what he would do differently, he said only that the company could have expanded global partnerships sooner, then defended its "cautious and sustainable approach" as the source of "long-term credibility."
Great operators are aggressive in their home domain and conservative outside it. Poonawalla bet heavily on vaccines, the business he understood better than anyone alive, and moved carefully in finance, where he was a newcomer. The asymmetry is the discipline. Confidence earned in one arena is not automatically transferable to another.
Tactic: For any adjacent venture, cap first-year exposure at a level whose total loss would not change your core strategy.
Principle 12
Write your own citation
Poonawalla wrote his PhD thesis on his own company's technology and its "socio-economic impact on the Society." His website notes that Oxford's honorary doctorate places him after Edward Jenner. He supplies the number, "more than 30 million human lives," that frames his legacy. When asked what he wants to be remembered for, he has a prepared answer: "That we never compromised on affordability."
This is not vanity alone. It is narrative control. A founder who does not define his contribution leaves others to define it: as a pandemic profiteer, as the father of a controversial CEO, as a billionaire with Sistine Chapel ceilings. Poonawalla chose his frame early and repeats it relentlessly, backed by specific numbers. The frame has largely held, even through the export-ban crisis and the Fincorp and Orchid controversies.
Tactic: Write the one-sentence answer to "What should you be remembered for?" now, and attach a number you can defend.
Free playbook
Get The Business Model Playbook
58 business models, one visual page each: how the money flows, the metrics that matter, and who runs it. Free when you join the Faster Than Normal email.
Free. No spam. Unsubscribe anytime.
Part IIIQuotes and Maxims
In their words
— Cyrus Poonawalla to Forbes Asia, November 2007We reach more children than Coca-Cola and PepsiCo can ever hope to.
— Cyrus Poonawalla to Forbes Asia, November 2007, on declining to list the Serum InstituteWe don't really need the money. And I don't fancy the idea of being answerable to anyone.
— Cyrus Poonawalla, Pune, August 2021, on India's vaccine export banMy son asked me not to open my mouth. But it is my view that exports ought to be opened.
— Cyrus Poonawalla to FinancialExpress.com, 2026, on his biggest achievementThat we never compromised on affordability. That was always the principle that a vaccine made by Serum should be accessible, not just to countries that could pay a premium, but to everyone.
— Cyrus Poonawalla to The Economic Times, 2026It has been a journey driven more by purpose than design.
Maxims
- Audit the outflows. Your most valuable asset may be what you are already giving away.
- Follow the politics to the customer. The force that kills your old market may be the buyer of your new one.
- Cheap at scale is a fortress. A price no one can match protects margins better than a price everyone can charge.
- Rent mastery before you own it. Hire the incumbent's best people and give them speed.
- One stamp can open a continent. Chase the credential that unlocks a whole class of buyers.
- Ownership buys discretion. You can only choose purpose over margin if no one can overrule you.
- Let the engine pay for the passion. Never ask a beloved business to carry your fortune.
- Build before you are asked. In a crisis, capacity already standing is the only capacity that counts.
- Praise precisely, criticise precisely. Specificity turns opposition into judgement.
- Keep the line whole. What is divided too many times becomes a name without a fortune.
